Skip to main content
. 2014 Nov 7;20(41):15110–15118. doi: 10.3748/wjg.v20.i41.15110

Table 4.

Phase II studies of S-1 for gemcitabine refractory pancreatic cancer

Ref. n ORR PFS (mo) MST (mo)
Morizane et al[34] 40 15.0% 2.0 4.5
Sudo et al[35] 21 9.5% 4.1 6.3

PFS: Progression-free survival; MST: Median survival time; ORR: Objective response rate.